Los Angeles Capital Management & Equity Research Inc. Has $525,000 Holdings in Cambrex Corporation (CBM)

Los Angeles Capital Management & Equity Research Inc. raised its position in Cambrex Corporation (NYSE:CBM) by 29.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,781 shares of the biotechnology company’s stock after acquiring an additional 2,020 shares during the quarter. Los Angeles Capital Management & Equity Research Inc.’s holdings in Cambrex Corporation were worth $525,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in CBM. Creative Planning increased its position in shares of Cambrex Corporation by 162.6% in the second quarter. Creative Planning now owns 1,765 shares of the biotechnology company’s stock valued at $105,000 after acquiring an additional 1,093 shares during the period. Nisa Investment Advisors LLC increased its position in shares of Cambrex Corporation by 9.3% in the second quarter. Nisa Investment Advisors LLC now owns 1,760 shares of the biotechnology company’s stock valued at $105,000 after acquiring an additional 150 shares during the period. Meeder Asset Management Inc. purchased a new position in shares of Cambrex Corporation in the first quarter valued at about $109,000. Ameritas Investment Partners Inc. purchased a new position in shares of Cambrex Corporation in the first quarter valued at about $151,000. Finally, Dubuque Bank & Trust Co. increased its position in shares of Cambrex Corporation by 3.3% in the second quarter. Dubuque Bank & Trust Co. now owns 2,697 shares of the biotechnology company’s stock valued at $161,000 after acquiring an additional 87 shares during the period. Hedge funds and other institutional investors own 98.28% of the company’s stock.

In related news, CEO Steven M. Klosk sold 12,000 shares of Cambrex Corporation stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $51.53, for a total value of $618,360.00. Following the completion of the sale, the chief executive officer now directly owns 95,328 shares in the company, valued at approximately $4,912,251.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 36,000 shares of company stock valued at $2,070,960 over the last quarter. 2.48% of the stock is owned by company insiders.

A number of equities research analysts have recently weighed in on CBM shares. BidaskClub lowered shares of Cambrex Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. ValuEngine lowered shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Zacks Investment Research lowered shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 4th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $64.00.

Shares of Cambrex Corporation (NYSE:CBM) opened at 54.05 on Monday. Cambrex Corporation has a 1-year low of $38.30 and a 1-year high of $62.95. The company’s 50-day moving average is $53.13 and its 200 day moving average is $55.08. The company has a market cap of $1.77 billion, a price-to-earnings ratio of 19.69 and a beta of 2.25.

Cambrex Corporation (NYSE:CBM) last released its earnings results on Friday, August 4th. The biotechnology company reported $0.76 EPS for the quarter, hitting analysts’ consensus estimates of $0.76. The company had revenue of $134.55 million during the quarter, compared to analysts’ expectations of $136.82 million. Cambrex Corporation had a net margin of 17.70% and a return on equity of 24.25%. Cambrex Corporation’s revenue for the quarter was up 13.4% on a year-over-year basis. During the same period last year, the business earned $0.68 EPS. Equities analysts anticipate that Cambrex Corporation will post $3.08 EPS for the current year.

WARNING: This article was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://ledgergazette.com/2017/09/25/los-angeles-capital-management-equity-research-inc-has-525000-holdings-in-cambrex-corporation-cbm.html.

Cambrex Corporation Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Institutional Ownership by Quarter for Cambrex Corporation (NYSE:CBM)

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply